截至目前，康宁杰瑞拥有或共同拥有全球27项与技术平台及产品管线相关的专利申请。研发团队在具有重要影响力的期刊上发表研究论文多篇。
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
了解详情
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
了解详情
Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance
了解详情
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
了解详情
